Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gautier Lefebvre

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bulletin Du Cancer|August 4, 2015
Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biasesEmmanuelle Fournier, Charles Fournier, Véronique Christophe, et al.
BMC Cancer|April 5, 2018
Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional studyCorinne Vannimenus, Hélène Bricout, Olivier Le Rouzic, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Lancet (London, England)|December 25, 2025
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialJean Bourhis, Anne Aupérin, Christian Borel, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bulletin Du Cancer|August 4, 2015
Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biasesEmmanuelle Fournier, Charles Fournier, Véronique Christophe, et al.
BMC Cancer|April 5, 2018
Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional studyCorinne Vannimenus, Hélène Bricout, Olivier Le Rouzic, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Lancet (London, England)|December 25, 2025
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialJean Bourhis, Anne Aupérin, Christian Borel, et al.
Pageof 2